Oxcarbazepine-induced hyponatremia, a cross-sectional study.
In order to estimate the frequency of hyponatremia in patients treated with oxcarbazepine (OxCZ), a cross-sectional study was carried out. 21 of 41 patients being treated with the drug were found to be hyponatremic (serum sodium levels less than 135 mmol/l). None was found to be hypernatremic (serum sodium levels greater than 145 mmol/l). A non-significant trend towards increasing frequency of hyponatremia with increasing age was observed. Patients treated with dosages above 30 mg/kg/day had a significantly higher risk of becoming hyponatremic.
Nielsen
O A
OA
University Clinic of Neurology, Hvidovre Hospital, Denmark.
Johannessen
A C
AC
Bardrum
B
B
D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D002220:Carbamazepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004827:Epilepsy / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007010:Hyponatremia / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D000078330:Oxcarbazepine
D000927:Anticonvulsants; D002220:Carbamazepine; D000078330:Oxcarbazepine